Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Dentistry

Why Does Dental Numbing Fail in hEDS?

At a Glance

Patients with hypermobile Ehlers-Danlos Syndrome (hEDS) often experience local anesthetic resistance because loose connective tissue causes numbing medicine to absorb too quickly. Dentists can overcome this by using Articaine, altering injection techniques, and starting work immediately.

In this answer

2 sections

01

Why Does Numbing Medicine Fail in hEDS?

02

Practical Strategies for Your Next Dental Visit

If numbing medicine (local anesthetic) doesn’t seem to work for you at the dentist, or wears off much faster than it should, you are not alone and it is not in your head. Increased rates of local anesthetic resistance are a widely recognized clinical reality for patients with hypermobile Ehlers-Danlos Syndrome (hEDS) [1]. While there are no universally standardized guidelines for managing this issue yet, your dental team can use alternative anesthetic agents, adjust their injection techniques, and carefully time procedures to ensure your visits are comfortable [1][2].

Why Does Numbing Medicine Fail in hEDS?

While clinical reports clearly indicate that hEDS patients experience local anesthetic resistance, the exact biological mechanisms remain multifactorial and are still actively researched by medical professionals [1][3]. Current theories include:

  • The Tissue Diffusion Theory: This is the most prominent theory, suggesting that the altered, looser connective tissue in hEDS allows the anesthetic fluid to diffuse (spread out) away from the injection site much faster than usual [4][5]. Because the medicine is quickly absorbed into surrounding tissues, it may not stay near the targeted nerve long enough, or in high enough concentrations, to properly block pain [6].
  • Nervous System and Inflammation: Researchers also suspect that systemic immune or inflammatory dysregulation, as well as central sensitization (a condition where the central nervous system becomes hyper-reactive to pain signals), may play a role in why anesthetics are less effective [7][8].
  • Sodium Channel Variations: Some theories have proposed that variations in sodium channels (proteins in nerve cells that control pain thresholds) could cause anesthetic failure. However, current medical literature has not proven a direct correlation between these specific genetic mutations and EDS [9][10].

Practical Strategies for Your Next Dental Visit

Because specific evidence-based guidelines for local anesthesia in hEDS are currently lacking, your dentist will need to rely on clinical experience and tailor their approach to your unique anatomy and needs [11][12].

If you have experienced pain during dental procedures despite being numbed, consider discussing the following strategies with your dental care team:

  • Request Articaine: Articaine is a specific type of local anesthetic frequently cited as more effective than standard lidocaine [13][14]. It has a faster onset, increased potency, and higher lipid (fat) solubility, allowing it to penetrate tissue and bone more efficiently to overcome resistance [15].
  • Re-evaluate Wait Times: Because your tissue may absorb the medicine rapidly, the standard dental practice of “injecting and leaving the room for 15 minutes” often fails for hEDS patients. Ask your dentist to stay in the room and begin work immediately once you feel numb, before the medicine wears off [1].
  • Utilize Alternative Injection Techniques: If a standard nerve block fails, dentists can use supplemental techniques to achieve profound numbness. These include buccal infiltration (injecting directly into the gum near the specific tooth), intraligamentary injections (injecting into the ligament around the tooth), or intraosseous injections (injecting directly into the bone) [16][17].
  • Navigate Epinephrine and Dysautonomia: Dentists often add epinephrine (adrenaline) to anesthetics to keep the numbing medication in the tissue longer. However, because many hEDS patients have comorbid Postural Orthostatic Tachycardia Syndrome (POTS) or other forms of dysautonomia (disorders of the autonomic nervous system), epinephrine can trigger severe tachycardia, heart palpitations, and dysautonomia flares [18][19]. It is vital to discuss this trade-off carefully with your dentist [20].
  • Monitor Maximum Safe Dosages: While you may require frequent “top-up” doses during a procedure, your dentist must strictly track the total amount given based on your body weight. Exceeding recommended limits risks Local Anesthetic Systemic Toxicity (LAST), a serious cardiovascular and neurological complication [21][22].
  • Schedule Longer Appointments: Booking extra time allows for necessary pauses to administer additional anesthetic without rushing or stressing you or your dentist.
  • Explore Sedation Dentistry: If local anesthetics consistently fail, conscious sedation (such as nitrous oxide or “laughing gas”) or deeper sedation options can be an effective way to manage pain and anxiety during dental work [2].

Common questions in this guide

Why does dental numbing wear off so fast if I have hEDS?
In hEDS, altered connective tissue may allow the anesthetic fluid to spread away from the injection site too quickly. This means the medicine is absorbed into surrounding tissues before it can properly block pain at the targeted nerve.
Is there a better dental numbing medicine for Ehlers-Danlos patients?
Many dentists find Articaine more effective than standard Lidocaine for patients with hEDS. Articaine has a faster onset and penetrates tissue and bone more efficiently, which helps overcome anesthetic resistance.
Why does dental numbing make my heart race?
Dentists often add epinephrine to anesthetics to keep the medicine working longer. If you have hEDS with co-occurring POTS or dysautonomia, this added epinephrine can trigger a rapid heart rate, palpitations, and dysautonomia flares.
What should my dentist do differently if I have hEDS?
Your dentist should avoid the standard approach of leaving the room after injecting, as the numbness may wear off before they return. Instead, they should stay in the room and begin the procedure immediately as soon as you feel numb.
What are my options if local anesthetics never work for me?
If standard numbing injections consistently fail, you can explore sedation options with your dentist. Conscious sedation, such as nitrous oxide (laughing gas), or deeper sedation can be highly effective ways to manage pain and anxiety during procedures.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my connective tissue disorder, how can we adapt standard injection techniques, such as trying intraligamentary or intraosseous injections, if the standard nerve block doesn't work?
  2. 2.Are you open to using Articaine instead of standard Lidocaine, given its higher tissue penetration rates?
  3. 3.Since my tissue absorbs anesthetics very quickly, can we agree that you will stay in the room and begin the procedure immediately once I feel numb?
  4. 4.How do you plan to track the total milligrams of anesthetic used to ensure I stay under my maximum safe dosage limit if I need multiple 'top-ups'?
  5. 5.Since I also have POTS/dysautonomia, how can we manage the use of epinephrine in the anesthetic to prevent a severe heart rate spike or flare?
  6. 6.Can we schedule a longer appointment block to ensure we have time for extra injections and pauses without either of us feeling rushed?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

What Are the 12 Systemic Signs of hEDS?What Are the Beighton Score Age Cutoffs for hEDS?hEDS Medical Gaslighting: Coping with Trauma & HealingWhy Does hEDS Cause Stomach and GI Issues?Is There a Genetic Test for Hypermobile EDS (hEDS)?hEDS vs Fibromyalgia Misdiagnosis: What's the Difference?How to Find a Doctor or Physical Therapist for hEDSWhat Are the Best MCAS Treatments for hEDS Patients?How to Use the Spoon Theory for hEDS FatigueWhat Are the Best Pain Management Strategies for hEDS?What Are the Best POTS Treatments for hEDS Patients?What Is a Physiatrist & Do I Need One for hEDS?What is HSD vs hEDS? Understanding the DifferenceWhy Is Stretching Bad for hEDS & Hypermobility?

References

References (22)
  1. 1

    Anesthetic Management for Ehlers-Danlos Syndrome, Hypermobility Type Complicated by Local Anesthetic Allergy: A Case Report.

    Cesare AE, Rafer LC, Myler CS, Brennan KB

    The American journal of case reports 2019; (20()):39-42 doi:10.12659/AJCR.912799.

    PMID: 30626862
  2. 2

    Heightened Revision Risk After Ankle Ligament Repair in Patients With Ehlers-Danlos Syndrome or Hypermobility Spectrum Disorder: A Propensity-Matched National Database Study.

    Dinh PV, Johnson JM, Reiad TA, et al.

    Foot & ankle international 2025; (46(11)):1231-1238 doi:10.1177/10711007251363246.

    PMID: 40954923
  3. 3

    Evidence for central sensitization as classified by the central sensitization inventory in patients with pain and hypermobility.

    Desai MJ, Brestle M, Jonely H

    Pain practice : the official journal of World Institute of Pain 2025; (25(1)):e13411 doi:10.1111/papr.13411.

    PMID: 39192465
  4. 4

    Fascial thickness and stiffness in hypermobile Ehlers-Danlos syndrome.

    Wang TJ, Stecco A

    American journal of medical genetics. Part C, Seminars in medical genetics 2021; (187(4)):446-452 doi:10.1002/ajmg.c.31948.

    PMID: 34741592
  5. 5

    Change in gliding properties of the iliotibial tract in hypermobile Ehlers-Danlos Syndrome.

    Wang TJ, Stecco A, Schleip R, et al.

    Journal of ultrasound 2023; (26(4)):809-813 doi:10.1007/s40477-023-00775-7.

    PMID: 36802027
  6. 6

    Bridging the Diagnostic Gap for Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders: Evidence of a Common Extracellular Matrix Fragmentation Pattern in Patient Plasma as a Potential Biomarker.

    Ritelli M, Chiarelli N, Cinquina V, et al.

    American journal of medical genetics. Part A 2025; (197(1)):e63857 doi:10.1002/ajmg.a.63857.

    PMID: 39225014
  7. 7

    Defining the Chronic Complexities of hEDS and HSD: A Global Survey of Diagnostic Challenges, Life-Long Comorbidities, and Unmet Needs.

    Daylor V, Griggs M, Weintraub A, et al.

    Journal of clinical medicine 2025; (14(16)) doi:10.3390/jcm14165636.

    PMID: 40869462
  8. 8

    KLK15 alters connective tissues in hypermobile Ehlers-Danlos syndrome.

    Gensemer C, Petrucci T, Beck T, et al.

    iScience 2025; (28(9)):113343 doi:10.1016/j.isci.2025.113343.

    PMID: 40949095
  9. 9

    Pain triangle phenomenon in possible association with SCN9A: A case report.

    Sopacua M, Hoeijmakers JGJ, van der Kooi AJ, et al.

    Molecular genetics & genomic medicine 2022; (10(10)):e2026 doi:10.1002/mgg3.2026.

    PMID: 36114697
  10. 10

    Nav1.7 is required for normal C-low threshold mechanoreceptor function in humans and mice.

    Middleton SJ, Perini I, Themistocleous AC, et al.

    Brain : a journal of neurology 2022; (145(10)):3637-3653 doi:10.1093/brain/awab482.

    PMID: 34957475
  11. 11

    The GoodHope Ehlers Danlos Syndrome Clinic: development and implementation of the first interdisciplinary program for multi-system issues in connective tissue disorders at the Toronto General Hospital.

    Mittal N, Mina DS, McGillis L, et al.

    Orphanet journal of rare diseases 2021; (16(1)):357 doi:10.1186/s13023-021-01962-7.

    PMID: 34376220
  12. 12

    'Pediatric Ehlers-Danlos syndrome VI with retroperitoneal Hemorrhage: case report and management strategy'.

    Yunus A, Khan M, Jamali AA, Kazi G

    Oxford medical case reports 2025; (2025(7)):omaf119 doi:10.1093/omcr/omaf119.

    PMID: 40718530
  13. 13

    Comparative Evaluation of Anesthetic Efficacy of 4% Articaine and 2% Lignocaine as Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis in Permanent Mandibular First Molars: A Double-Blinded Randomized Clinical Trial.

    Chakraborty S, Pakyntein M, Kataki R, et al.

    Cureus 2025; (17(7)):e89090 doi:10.7759/cureus.89090.

    PMID: 40895880
  14. 14

    Efficacy of articaine vs lignocaine in maxillary and mandibular infiltration and block anesthesia in the dental treatments of adults: A systematic review and meta-analysis.

    Soysa NS, Soysa IB, Alles N

    Journal of investigative and clinical dentistry 2019; (10(3)):e12404 doi:10.1111/jicd.12404.

    PMID: 30887677
  15. 15

    Is articaine more effective than lidocaine in patients with irreversible pulpitis? An umbrella review.

    Nagendrababu V, Duncan HF, Whitworth J, et al.

    International endodontic journal 2020; (53(2)):200-213 doi:10.1111/iej.13215.

    PMID: 31491042
  16. 16

    How Successful is Supplemental Intraseptal and Buccal Infiltration Anaesthesia in the Mandibular Molars of Patients Undergoing Root Canal Treatment or Tooth Extraction?

    Gazal G, Bahabri R, Alolayan AB, et al.

    Journal of oral & maxillofacial research 2020; (11(1)):e5 doi:10.5037/jomr.2020.11105.

    PMID: 32377329
  17. 17

    Different anesthetics on the efficacy of inferior alveolar nerve block in patients with irreversible pulpitis: A network systematic review and meta-analysis.

    Larocca de Geus J, Nogueira da Costa JK, Wambier LM, et al.

    Journal of the American Dental Association (1939) 2020; (151(2)):87-97.e4 doi:10.1016/j.adaj.2019.09.002.

    PMID: 31813471
  18. 18

    Comorbidities and neurosurgical interventions in a cohort with connective tissue disorders.

    Ruhoy IS, Bolognese PA, Rosenblum JS, et al.

    Frontiers in neurology 2024; (15()):1484504 doi:10.3389/fneur.2024.1484504.

    PMID: 39931100
  19. 19

    Cardiovascular Symptoms, Dysautonomia, and Quality of Life in Adult and Pediatric Patients with Hypermobile Ehlers-Danlos Syndrome: A Brief Review.

    Hertel A, Black WR, Malloy Walton L, et al.

    Current cardiology reviews 2024; doi:10.2174/011573403X271096231203164216.

    PMID: 38275067
  20. 20

    Cardiovascular, autonomic symptoms and quality of life in children with hypermobile Ehlers-Danlos syndrome.

    Hertel AK, Black WR, Lytch A, et al.

    SAGE open medicine 2024; (12()):20503121241287073 doi:10.1177/20503121241287073.

    PMID: 39420997
  21. 21

    Apparent local anesthetic systemic toxicity following activation of an epidural catheter for cesarean delivery: diagnosis and management of an uncommon obstetric anesthesia complication.

    Soliman Y, Hatfield AA, McAllister RK, et al.

    Proceedings (Baylor University. Medical Center) 2024; (37(5)):874-876 doi:10.1080/08998280.2024.2357522.

    PMID: 39165828
  22. 22

    Population pharmacokinetic and safety analysis of ropivacaine used for erector spinae plane blocks.

    Schwenk ES, Lam E, Abulfathi AA, et al.

    Regional anesthesia and pain medicine 2023; (48(9)):454-461 doi:10.1136/rapm-2022-104252.

    PMID: 37085287

This page provides educational information about dental anesthetic resistance in hEDS. Always consult your dentist and healthcare providers to determine the safest pain management strategy for your specific condition.

Get notified when new evidence is published on Hypermobile Ehlers-Danlos Syndrome (hEDS).

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.